Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] Based on its super earnings for H1 of FY23, the IPO is fully priced discounting all near-term positives. The sustainability of such margins going forward is a major concern. The segment too is becoming crowded and highly competitive. Post-IPO small paid-up equity also indicates longer gestation for migration to the main board. Well-informed investors may park funds with a long-term perspective. Read detail review...
Aristo Bio-Tech IPO Reviews, analysis and views by popular members. Read Aristo Bio-Tech & Lifescience Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP